Vytrus Biotech - Public Comps and Valuation Multiples

Vytrus Biotech Overview

About Vytrus Biotech

Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.

Founded

2009

HQ

Employees

n/a

Website

vytrus.com

Sectors

Drug Development & Therapeutics
Biopharmaceuticals
BioTech

Financials

LTM Revenue $10.1M

LTM EBITDA $4.6M

EV

$89.6M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Vytrus Biotech Financials

As of January 2026, Vytrus Biotech reported last 12-month revenue of $10.1M and EBITDA of $4.6M.

In the same period, Vytrus Biotech achieved $3.2M in LTM net income.

See Vytrus Biotech valuation multiples based on analyst estimates

Vytrus Biotech P&L

In the most recent fiscal year, Vytrus Biotech reported revenue of $6.0M and EBITDA of $2.2M.

Vytrus Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Vytrus Biotech valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$10.1M	XXX	$6.0M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$6.5M	XXX	XXX	XXX
Gross Margin	n/a	XXX	109%	XXX	XXX	XXX
EBITDA	$4.6M	XXX	$2.2M	XXX	XXX	XXX
EBITDA Margin	46%	XXX	36%	XXX	XXX	XXX
EBIT	$3.5M	XXX	$1.2M	XXX	XXX	XXX
EBIT Margin	35%	XXX	20%	XXX	XXX	XXX
Net Profit	$3.2M	XXX	$1.2M	XXX	XXX	XXX
Net Margin	31%	XXX	20%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Vytrus Biotech including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $10.1M. EBITDA for the last twelve months was $4.6M. In the most recent fiscal year, Vytrus Biotech achieved $6.0M in revenue and $2.2M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$10.1M	Analyst estimates available to subscribers	$6.0M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$6.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	109.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$4.6M	Analyst estimates available to subscribers	$2.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	46.1% EBITDA margin	Analyst estimates available to subscribers	36.4% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$3.5M	Analyst estimates available to subscribers	$1.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	34.7% EBIT margin	Analyst estimates available to subscribers	19.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$3.2M	Analyst estimates available to subscribers	$1.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	31.5% net profit margin	Analyst estimates available to subscribers	20.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Vytrus Biotech

This financial data table provides comprehensive performance metrics for Vytrus Biotech, a company based in Spain. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Vytrus Biotech generated $10.1M in revenue over the last twelve months.
The company achieved $4.6M in EBITDA over the last twelve months.
Net income over the last twelve months reached $3.2M.

Fiscal Year Performance

In the most recent fiscal year, Vytrus Biotech reported $6.0M in total revenue.
Fiscal year EBITDA was $2.2M.
The company maintained a gross profit margin of 109.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 36.4%.
Net profit margin reached 20.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Vytrus Biotech. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Vytrus Biotech Stock Performance

Vytrus Biotech has current market cap of EUR 76.8M (or $90.8M), and EV of EUR 75.8M (or $89.6M).

Market Cap Evolution

Vytrus Biotech Stock Data

As of February 4, 2026, Vytrus Biotech's stock price is EUR 11 (or $13).

See Vytrus Biotech trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$89.6M	$90.8M	XXX	XXX	XXX	XXX	$0.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Vytrus Biotech Valuation Multiples

Vytrus Biotech's trades at 8.9x EV/Revenue multiple, and 19.3x EV/EBITDA.

See valuation multiples for Vytrus Biotech and 15K+ public comps

Vytrus Biotech Financial Valuation Multiples

As of February 4, 2026, Vytrus Biotech has market cap of $90.8M and EV of $89.6M.

Equity research analysts estimate Vytrus Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vytrus Biotech has a P/E ratio of 28.7x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$90.8M	XXX	$90.8M	XXX	XXX	XXX
EV (current)	$89.6M	XXX	$89.6M	XXX	XXX	XXX
EV/Revenue	8.9x	XXX	8.9x	XXX	XXX	XXX
EV/EBITDA	19.3x	XXX	19.3x	XXX	XXX	XXX
EV/EBIT	25.7x	XXX	25.7x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	28.7x	XXX	28.7x	XXX	XXX	XXX
EV/FCF	n/a	XXX	118.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vytrus Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Vytrus Biotech Margins & Growth Rates

Vytrus Biotech's last 12 month revenue growth is 25%

Vytrus Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Vytrus Biotech's rule of 40 is 57% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vytrus Biotech's rule of X is 109% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Vytrus Biotech and other 15K+ public comps

Vytrus Biotech Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	25%	XXX	23%	XXX	XXX	XXX
EBITDA Margin	46%	XXX	46%	XXX	XXX	XXX
EBITDA Growth	31%	XXX	82%	XXX	XXX	XXX
Rule of 40	57%	XXX	71%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	109%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	89%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial